Intralink-Spine expands clinical trials for injectable product

Spinal device company Intralink-Spine has expanded clinical trials of its Rejuve device in Australia, according to a July 14 news release.

Advertisement

Three things to know:

1. Rejuve is an injectable device that strengthens and stabilizes the degenerated disc.

2. Performed on an outpatient basis, Rejuve can be used as an adjunct or replacement to surgeries, including discectomies, spinal fusions and spinal implants.

3. The device is intended for the treatment of degenerative disc disease, lumbar pain and associated spinal diseases.

More articles on devices:
Setting spine practices up for success post-pandemic: 5 industry insights
UAMS begins data gathering initiative with spine patients
3 spine surgeons on the move in June

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.